APO-PINDOL TAB 15MG TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PINDOLOL

から入手可能:

APOTEX INC

ATCコード:

C07AA03

INN（国際名）:

PINDOLOL

投薬量:

15MG

医薬品形態:

TABLET

構図:

PINDOLOL 15MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

BETA-ADRENERGIC BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0112362002; AHFS:

認証ステータス:

MARKETED

承認日:

1988-12-31

製品の特徴

Page 1 of 28
PRODUCT MONOGRAPH
PR
APO-PINDOL
(Pindolol tablets U.S.P.)
Tablets 5, 10 and 15 mg
Antihypertensive/Antianginal Agent
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Control No: 219137
DATE OF REVISION:
October 12, 2018
Page 2 of 28
NAME OF DRUG
PR
APO-PINDOL
(Pindolol tablets U.S.P.)
Tablets 5, 10 and 15 mg
THERAPEUTIC CLASSIFICATION
Antihypertensive/Antianginal Agent
ACTIONS
APO-PINDOL (pindolol) is a β-adrenergic-receptor - blocking agent
which possesses
partial agonist activity (intrinsic sympathomimetic activity-I.S.A.).
It is used in the treatment
of hypertension and/or the prophylaxis of angina pectoris.
Hypertension
The mechanism of the antihypertensive effect of pindolol has not been
established. Among
the factors that may be involved are:
(a)
competitive ability to antagonize catecholamine-induced tachycardia at
the β-receptor
sites in the heart, thus decreasing cardiac output
(b)
a reduction in total peripheral resistance
(c)
inhibition of the vasomotor centres
(d)
inhibition of renin release by the kidneys
Angina Pectoris
The mechanism of the antianginal effect of pindolol has not been
established. Pindolol may
reduce the oxygen requirement of the heart at any level of effort by
blocking
catecholamine-induced increases in the heart rate, systolic blood
pressure, and the velocity
and extent of myocardial contraction. However, oxygen requirements may
be increased by
such actions as increases in left ventricular fibre length, end
diastolic pressure and the
systolic ejection period. When the net effect is beneficial in
patients with angina, it
manifests itself during exercise or stress by delaying the onset of
pain and reducing the
incidence and severity of anginal attacks.
In man, orally-administered pindolol is rapidly and almost completely
absorbed (≥95%)
from the gastrointestinal tract. The mean absolute bioavailability
after oral administration is
about 87 to 92%. Plasma levels of 10 to 30 nanogram/mL are associated
with its
therapeutic efficacy. Following single dose administra